Anavar and Birth Control: What Happens When a Steroid That Suppresses SHBG Meets a Contraceptive That Raises It

Of all the drug interactions covered in this Anavar content library, this one may be the most practically consequential for the largest number of women, and it is the one with the least clinical data to guide it. Millions of women use hormonal contraceptives. A growing number of those women also use Anavar. And not a single clinical study has ever examined what happens when these two classes of compound interact inside the same body. What we have instead are pharmacological first principles: the known mechanisms of each compound, the pathways they share, the directions they push the same biomarkers, and the theoretical interactions that follow from combining two drugs that both undergo hepatic first-pass metabolism, both alter sex hormone-binding globulin in opposite directions, and both increase the risk of a rare but serious adverse event that neither produces frequently alone. This article assembles those first principles into the most complete picture the current evidence allows. It is not a clinical trial. But for the woman taking her combined oral contraceptive pill every morning and her Anavar tablet every evening, it is the only pharmacologically grounded analysis available anywhere. At Hemi Pharma UK, we consider that gap unacceptable, and this article is our attempt to fill it.

Why Do Anavar and the Combined Oral Contraceptive Pull SHBG in Opposite Directions, and Why Does That Matter?

Sex hormone-binding globulin is a transport protein produced by the liver that binds and inactivates circulating sex steroids, including testosterone, dihydrotestosterone, and oestradiol. The level of SHBG in your blood determines how much of each hormone is biologically active (free) and how much is bound and inert. SHBG is not a passive bystander. It is a regulatory mechanism, and both Anavar and hormonal contraceptives manipulate it, but in opposite directions.

Combined oral contraceptives containing ethinyl estradiol (EE) increase SHBG production. This is one of the therapeutic mechanisms by which COCs treat acne and hirsutism: higher SHBG binds more free testosterone and DHT, reducing the androgenic stimulation of sebaceous glands and hair follicles. The FDA-approved labelling for COCs such as Ortho Tri-Cyclen explicitly states that the combination of ethinyl estradiol and norgestimate “increases sex hormone binding globulin and decreases free testosterone” (Ortho Tri-Cyclen FDA label). SHBG elevations of 200 to 400% above baseline are commonly observed in COC users.

Anavar does the opposite. As documented extensively across our existing content (our Anavar and oestrogen article, our Anavar on TRT article, and our Anavar vs Proviron article), oxandrolone suppresses SHBG production through a hepatic mechanism. In male users at bodybuilding doses, SHBG can drop to single digits. In female users at lower doses (5mg to 10mg daily), the suppression is less dramatic but still measurable.

When a woman takes both a COC and Anavar simultaneously, these two opposing forces compete. The COC is driving SHBG upward through EE-mediated hepatic stimulation. The Anavar is driving SHBG downward through androgen-mediated hepatic suppression. The net SHBG level depends on the relative potency of each stimulus, which depends on the specific COC formulation (higher EE doses produce more SHBG elevation), the Anavar dose, and the individual’s hepatic responsiveness.

The practical consequence of this tug-of-war is that the COC’s anti-androgenic benefit (the acne improvement, the hirsutism reduction, the free testosterone suppression) may be partially or fully negated by Anavar’s SHBG suppression. A woman who takes a COC specifically for acne control may find that Anavar reverses the improvement by reducing the SHBG that was suppressing her free androgens. Conversely, a woman who takes Anavar for its performance effects may find that the COC blunts the SHBG suppression that amplifies the drug’s anabolic impact.

Could Anavar Reduce the Contraceptive Effectiveness of the Pill?

This is the question that carries the most serious clinical consequence, and the honest answer is: we do not know, because it has never been tested. What we can do is assess the theoretical risk using the FDA’s own framework for evaluating drug interactions with combined oral contraceptives.

The FDA guidance on clinical drug interaction studies with COCs, published in 2020, identifies CYP3A4 induction as the primary mechanism by which co-administered drugs reduce COC efficacy. Ethinyl estradiol is metabolised by CYP3A4, CYP2C9, and UGT enzymes. Progestins (levonorgestrel, norethindrone, desogestrel’s active metabolite etonogestrel) are metabolised primarily by CYP3A4. Drugs that induce CYP3A4 accelerate the metabolism of both EE and the progestin, lowering their plasma concentrations and potentially allowing ovulation to occur despite continued pill use (FDA Clinical DDI Guidance, 2020).

Oxandrolone is not a known CYP3A4 inducer. It undergoes hepatic metabolism (72% of the dose is metabolised hepatically, 28% excreted unchanged through the kidneys, as described in our Anavar kidney damage article), but it has not been characterised as a CYP enzyme inducer or inhibitor in formal interaction studies. The theoretical risk of Anavar reducing COC efficacy through CYP3A4 induction is therefore low but not zero, because no study has formally excluded it.

The more plausible interaction pathway is not enzymatic but protein-binding-related. If Anavar reduces SHBG (which binds some progestins, including levonorgestrel), then the free fraction of the progestin may increase, which could paradoxically enhance rather than reduce contraceptive efficacy in the short term. However, altered protein binding also changes the drug’s clearance rate, and the net effect on steady-state progestin levels is difficult to predict without measured data.

The responsible clinical position is this: Anavar probably does not reduce COC efficacy, but “probably” is not the same as “proven,” and the consequence of being wrong (pregnancy with a category X drug on board) is catastrophic. Women using Anavar should not rely on their COC as their sole contraceptive method. Adding a barrier method (condom) during the Anavar cycle and for one full menstrual cycle after stopping provides a safety margin that the theoretical analysis cannot.

How Does Combining Anavar and the Pill Compound Hepatic Stress?

Both ethinyl estradiol and oxandrolone undergo hepatic first-pass metabolism. Both produce measurable hepatic effects. The combination places the liver under a dual pharmacological load that neither compound produces alone.

Ethinyl estradiol is associated with cholestatic liver injury (the same injury pattern that oral AAS produce, as described in our Anavar and alcohol article), hepatic adenoma formation (a rare but documented complication of prolonged COC use), and alterations in hepatic protein synthesis (including the SHBG elevation described above, but also changes in clotting factor production). The FDA labelling for COCs lists hepatic neoplasia and cholestasis among the serious adverse reactions.

Oxandrolone produces its own mild cholestatic stress through the 17-alpha-alkylation mechanism documented across our content. When a woman takes both a COC and Anavar, her liver is processing two cholestasis-producing compounds simultaneously. The hepatic burden is additive. Mid-cycle liver function tests (ALT, AST, GGT, bilirubin) become especially important for women using both compounds. If transaminases rise above 2x ULN during combined use, reducing the Anavar dose or discontinuing one of the two compounds is warranted, because the dual cholestatic load increases the probability of progression to clinically significant liver injury.

Does Combining Anavar and Birth Control Increase Thrombotic Risk?

This is the interaction that carries the greatest theoretical severity, and it operates through two independent but converging pathways.

Combined oral contraceptives increase the risk of venous thromboembolism (VTE) by a factor of 2 to 6 compared to non-use. The mechanism involves EE-mediated increases in hepatic production of clotting factors (particularly factor VII, factor X, and fibrinogen) and decreases in natural anticoagulants (antithrombin III, protein S). The absolute risk remains low (approximately 3 to 9 VTE events per 10,000 woman-years of COC use, compared to 1 to 5 per 10,000 in non-users), but it is the most serious recognised adverse effect of hormonal contraception.

Anavar independently increases haematocrit through mild erythropoietic stimulation. Elevated haematocrit increases blood viscosity, which increases the resistance to flow and the probability of thrombus formation, particularly in venous beds where flow is already slow. As described in our Anavar bloodwork guide, haematocrit above 0.52 (52%) is the threshold at which the BJGP guideline recommends AAS cessation.

The combination of COC-mediated clotting factor alterations and Anavar-mediated haematocrit elevation creates two independent prothrombotic stimuli operating simultaneously. Neither alone produces a high absolute risk of VTE. Together, they may produce a risk that exceeds the sum of their individual contributions, because the mechanisms are synergistic: more clotting factors circulating in more viscous blood through the same venous system.

Women with additional risk factors for VTE (obesity, smoking, family history of thrombosis, age over 35, immobility from travel or injury) should consider this interaction particularly carefully. For women with no additional risk factors, the absolute VTE risk during a short-duration Anavar cycle remains low. For women with one or more additional risk factors, the compounded risk may warrant switching from a COC to a non-oestrogen-containing contraceptive method (progestin-only pill, hormonal IUD, or copper IUD) for the duration of the Anavar cycle, because oestrogen-free methods do not carry the clotting factor elevation that drives the COC’s thrombotic risk.

Which Contraceptive Methods Are Safest to Use Alongside Anavar?

The safest contraceptive methods during an Anavar cycle are those that do not add hepatic load, do not alter clotting factors, and are not affected by SHBG changes.

The copper IUD (non-hormonal) is pharmacologically inert: no hepatic metabolism, no clotting factor changes, no SHBG interaction, no theoretical interaction with Anavar at any level. It is the cleanest contraceptive option during any AAS cycle.

The hormonal IUD (levonorgestrel-releasing, such as the Mirena) delivers progestin locally to the uterus with minimal systemic absorption. It does not contain oestrogen, does not elevate clotting factors, and produces negligible systemic hormonal effects. It is a strong second choice.

The progestin-only pill (mini-pill) avoids the EE component and its associated SHBG elevation, hepatic stress, and clotting factor changes. However, it still undergoes hepatic metabolism (CYP3A4 for some progestins), creating a theoretical (untested) interaction pathway with Anavar’s hepatic effects.

The combined oral contraceptive pill remains an option if you are already established on it and do not wish to change methods. The interactions described in this article are theoretical, not proven. But adding a barrier method during the Anavar cycle provides a safety margin, the hepatic monitoring described above is essential, and the thrombotic risk should be assessed against your individual VTE risk factors.

Frequently Asked Questions

Will Anavar stop my birth control pill from working?

Almost certainly not through the CYP3A4 mechanism that causes most drug interactions with COCs (Anavar is not a known CYP3A4 inducer). However, the interaction has never been tested in a clinical study, and the SHBG and protein-binding changes could theoretically alter progestin pharmacokinetics in unpredictable ways. Given that oxandrolone is FDA pregnancy category X (foetal virilisation risk), adding a barrier method during your Anavar cycle provides a safety margin that the theoretical analysis alone cannot guarantee.

Should I stop my pill while taking Anavar?

No. Stopping your COC eliminates your contraceptive protection entirely, which is worse than the theoretical partial reduction in efficacy that the interaction might produce. Continue your COC and add a barrier method. If you are concerned about the compounded hepatic and thrombotic stress, discuss switching to a non-oestrogen method (hormonal IUD or copper IUD) with your GP before starting the Anavar cycle, not during it.

Will Anavar make my acne worse if I take the pill for skin?

Possibly. COCs improve acne by raising SHBG, which binds free testosterone and reduces androgenic stimulation of sebaceous glands. Anavar suppresses SHBG, which may partially reverse this effect. The net outcome depends on the balance between your COC’s SHBG-elevating effect and Anavar’s SHBG-suppressing effect. At low Anavar doses (5mg daily), the COC’s SHBG elevation may still predominate. At higher doses (10mg to 20mg daily), the Anavar may overcome the COC’s effect and acne may return or worsen.

Does the type of birth control pill matter for this interaction?

Yes. COCs with higher ethinyl estradiol content (30mcg to 35mcg EE) produce more SHBG elevation and more clotting factor changes than lower-dose formulations (20mcg EE). The progestin component also matters: anti-androgenic progestins (drospirenone, cyproterone acetate) provide additional SHBG elevation and androgen receptor antagonism that may partially offset Anavar’s androgenic effects. Androgenic progestins (levonorgestrel, norgestrel) do not provide this counterbalance. If you are choosing or changing a COC specifically because you plan to use Anavar, a formulation with an anti-androgenic progestin provides the most pharmacological counterbalance.

Is there any blood test I should do before combining Anavar and birth control?

Yes. A baseline panel before starting the combination should include: full blood count with haematocrit (to establish your starting point for thrombotic risk assessment), liver function (ALT, AST, GGT, bilirubin, to establish hepatic baseline before the dual load), fasting lipid panel (both compounds affect lipids), and SHBG (to document the COC-elevated baseline before Anavar suppresses it). A mid-cycle panel at week 3 to 4 of Anavar use should repeat all of these. If haematocrit rises above 48% (the threshold becomes lower when COC-mediated clotting factor elevation is present), or if ALT rises above 2x ULN, dose reduction or discontinuation of one compound is warranted.